Companies/Avicanna Inc.

Company profile

Avicanna Inc.

OTC: AVCNF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Toronto, ONReports USD

#557 of 1,394 Healthcare companies by revenue37th-percentile growth

EA Score

54D

FH 56DQ —GM 54SS 44

v0.1 · 45/100 weight · provisional

↑ 3-yr revenue growth, return on assets · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

$18.7M

Rev growth YoY (TTM)

+2.7%

Net income (FY)

-$2.0M

Employees

Market cap

$11.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$18.2M25.5M CAD2025

Net income-$2.0M-2.8M CAD2025

Operating income-$1.9M-2.7M CAD2025

Total assets$15.5M21.2M CAD2025

Liabilities$7.2M9.8M CAD2025

Equity$2.1M2.8M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$91.0k

FY18

$126.8k

FY19

$1.2M

FY20

$2.6M

FY21

$3.1M

FY22

$12.4M

FY23

$18.6M

FY24

$18.2M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Avicanna Inc. booked $18.2M in FY2025 revenue, contracting 2.0% year over year — slower than 63% of Healthcare companies we track, at a -11.2% net margin.

Peers · Healthcare

Cadrenal Therapeutics, Inc. Common Stock——VYNE Therapeutics Inc.38D Lexaria Bioscience Corp.43D Phio Pharmaceuticals Corp.40D

Key facts

CEOAras Azadian Mba

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersToronto, ON

ExchangeOTC: AVCNF

Employees87

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.